Peptide Receptor Radionuclide Therapy (PRRT) in a Patient Affected by Metastatic Breast Cancer with Neuroendocrine Differentiation | Zendy

Giordano Savelli | Zendy; Alberto Zaniboni | Zendy; Francesco Bertagna | Zendy; Giovanni Bosio | Zendy; Lutfun Nisa | Zendy; Carlo Rodella | Zendy; Giorgio Biasiotto | Zendy; Giovanni Bettinsoli | Zendy; Elena Migliorati | Zendy; Alessia Peli | Zendy; Roberta Falchi | Zendy; Francesca Giuffrida | Zendy; Raffaele Giubbini | Zendy

Open Access

Peptide Receptor Radionuclide Therapy (PRRT) in a Patient Affected by Metastatic Breast Cancer with Neuroendocrine Differentiation

Author(s) -

Giordano Savelli,

Alberto Zaniboni,

Francesco Bertagna,

Giovanni Bosio,

Lutfun Nisa,

Carlo Rodella,

Giorgio Biasiotto,

Giovanni Bettinsoli,

Elena Migliorati,

Alessia Peli,

Roberta Falchi,

Francesca Giuffrida,

Raffaele Giubbini

Publication year - 2012

Publication title -

breast care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.767

H-Index - 30

eISSN - 1661-3805

pISSN - 1661-3791

DOI - 10.1159/000343612

Subject(s) - radionuclide therapy , medicine , peptide receptor , somatostatin receptor , metastatic breast cancer , neuroendocrine tumors , breast cancer , oncology , neuroendocrine differentiation , cancer , somatostatin , receptor , prostate cancer

Breast cancer (BC) is the most frequent cancer in European women with nearly 30% of the patients eventually developing metastases. Neuroendocrine differentiation is a rare event, but overexpression of somatostatin receptors in BC has been reported in many studies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research